Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
02:01pm, Tuesday, 19'th May 2026
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the D
BioMarin's genetic disease therapy shows mixed results in late-stage study
09:24am, Monday, 18'th May 2026
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
09:05am, Monday, 18'th May 2026
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a rem
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
03:48pm, Wednesday, 06'th May 2026
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
02:20pm, Tuesday, 05'th May 2026
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
09:33pm, Monday, 04'th May 2026
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
08:30pm, Monday, 04'th May 2026
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
06:20pm, Monday, 04'th May 2026
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago.
BioMarin Reports First Quarter 2026 Financial and Operating Results
04:05pm, Monday, 04'th May 2026
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Tuesday, 28'th Apr 2026
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Completes Acquisition of Amicus Therapeutics
08:44am, Monday, 27'th Apr 2026
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects
Pre-Market Stock Futures: The futures are trading lower as we get set to start a new trading week, and after last week's string of record highs, it may be tough to duplicate the stellar performance th
